RT Journal Article
SR Electronic
T1 The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21256087
DO 10.1101/2021.04.26.21256087
A1 Ahmed Zaqout
A1 Joanne Daghfal
A1 Israa Alaqad
A1 Saleh A.N. Hussein
A1 Abdullah Aldushain
A1 Muna A. Almaslamani
A1 Mohammed Abukhattab
A1 Ali S. Omrani
YR 2021
UL http://medrxiv.org/content/early/2021/04/28/2021.04.26.21256087.abstract
AB Objective We herein report the initial impact of a national BNT162b2 rollout on SARS-CoV-2 infections in Qatar.Methods We included all individuals who by 16 March 2021 had completed ≥14 days of follow up after the receipt of BNT162b2. We calculated incidence rates (IR) and their 95% confidence intervals (CI), during days 1–7, 8–14, 15–21, 22–28, and >28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period.Results We included 199,219 individuals with 6,521,124 person-days of follow up. SARS-CoV-2 infection was confirmed in 1,877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7–18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8–84.7% during days 15–21, days 22–28, and >28 days (P <0.001 for each). For severe COVID-19, the incidence rates were 75.7– 93.3% lower (P <0.001 for each) during the corresponding time periods.Conclusion Our results are consistent with an early protective effect of BNT162b2 against all degrees of SARS-CoV-2 severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe publication of this report was funded by Qatar National Library. No other funding was required.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Hamad Medical Corporation Institutional Review Board with a waiver of informed consent (MRC-01-21-207).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.